Regulating Mammalian Target of Rapamycin To Tune Vaccination-Induced CD8+ T Cell Responses for Tumor Immunity

Vaccine strategies aimed at generating CD8+ T cell memory responses are likely to show augmented efficacy against chronic challenges like tumor. The abundance in variety of memory CD8+ T cells behooves development of vaccine strategies that generate distinct memory responses and evaluate them for tumor efficacy. In this study, we demonstrate the ability of a variety of rapamycin treatment regimens to regulate virus vaccination-induced CD8+ T cell memory responses and tumor efficacy. Strikingly, a short course of high-dose, but not low-dose, rapamycin treatment transiently blocks viral vaccination-induced mammalian target of rapamycin activity in CD8+ T cells favoring persistence and Ag-recall responses over type 1 effector maturation; however, prolonged high-dose rapamycin administration abrogated memory responses. Furthermore, a short course of high-dose rapamycin treatment generated CD8+ T cell memory responses that were independent of IL-15 and IL-7 and were programmed early for sustenance and greater tumor efficacy. These results demonstrate the impact a regimen of rapamycin treatment has on vaccine-induced CD8+ T cell responses and indicates that judicious application of rapamycin can augment vaccine efficacy for chronic challenges.

[1]  Qingsheng Li,et al.  A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. , 2011, Immunity.

[2]  P. Worley,et al.  The mammalian Target of Rapamycin (mTOR) regulates T helper cell differentiation through the selective activation of mTORC1 and mTORC2 signaling , 2011, Nature Immunology.

[3]  Qingsheng Li,et al.  Fine-tuning CD8+ T-cell functional responses: mTOR acts as a rheostat for regulating CD8+ T-cell proliferation, survival and differentiation? , 2010, Cell cycle.

[4]  Qingsheng Li,et al.  The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. , 2010, Immunity.

[5]  S. Jameson,et al.  Diversity in T cell memory: an embarrassment of riches. , 2009, Immunity.

[6]  R. Marcén,et al.  Immunosuppressive Drugs in Kidney Transplantation , 2009, Drugs.

[7]  Russell G. Jones,et al.  Enhancing CD8 T-cell memory by modulating fatty acid metabolism , 2009, Nature.

[8]  P. Worley,et al.  The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. , 2009, Immunity.

[9]  R. Ahmed,et al.  mTOR regulates memory CD8 T cell differentiation , 2009, Nature.

[10]  B. Kahan,et al.  Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine. , 2008, Transplantation proceedings.

[11]  W. Telford,et al.  Ex Vivo Rapamycin Generates Apoptosis-Resistant Donor Th2 Cells That Persist In Vivo and Prevent Hemopoietic Stem Cell Graft Rejection1 , 2008, The Journal of Immunology.

[12]  Nikhil S. Joshi,et al.  Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. , 2007, Immunity.

[13]  K. Guan,et al.  Expanding mTOR signaling , 2007, Cell Research.

[14]  Alan D. Roberts,et al.  Activation phenotype, rather than central– or effector–memory phenotype, predicts the recall efficacy of memory CD8+ T cells , 2007, The Journal of experimental medicine.

[15]  S. Vogel,et al.  Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming , 2007, Proceedings of the National Academy of Sciences.

[16]  J. Powell,et al.  A Role for Mammalian Target of Rapamycin in Regulating T Cell Activation versus Anergy1 , 2007, The Journal of Immunology.

[17]  D. Sabatini.  mTOR and cancer: insights into a complex relationship , 2006, Nature Reviews Cancer.

[18]  E. Wherry,et al.  Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin , 2005, Nature Immunology.

[19]  E. Jaffee,et al.  Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response , 2005, The Journal of experimental medicine.

[20]  D. Speiser,et al.  Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. , 2005, The Journal of clinical investigation.

[21]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[22]  J. Harty,et al.  CD8+ T cell contraction is controlled by early inflammation , 2004, Nature Immunology.

[23]  E. Ingulli,et al.  Development of a Novel Transgenic Mouse for the Study of Interactions Between CD4 and CD8 T Cells During Graft Rejection , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  V. Engelhard,et al.  Route of Immunization with Peptide-pulsed Dendritic Cells Controls the Distribution of Memory and Effector T Cells in Lymphoid Tissues and Determines the Pattern of Regional Tumor Control , 2003, The Journal of experimental medicine.

[25]  J. Curtsinger,et al.  Signal 3 Determines Tolerance versus Full Activation of Naive CD8 T Cells , 2003, The Journal of experimental medicine.

[26]  Yao-Tseng Chen,et al.  CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Donald E Ingber,et al.  Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV‐1 envelope , 2002, The EMBO journal.

[28]  J. Barretina,et al.  Human Immunodeficiency Virus 1 Envelope Glycoprotein Complex-Induced Apoptosis Involves Mammalian Target of Rapamycin/Fkbp12-Rapamycin–Associated Protein–Mediated P53 Phosphorylation , 2001, The Journal of experimental medicine.

[29]  Stephen P. Schoenberger,et al.  Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation , 2001, Nature Immunology.

[30]  J. Schlom,et al.  A triad of costimulatory molecules synergize to amplify T-cell activation. , 1999, Cancer research.

[31]  J. Allison,et al.  Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.

[32]  R. Schwartz,et al.  Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. , 1999, Journal of immunology.

[33]  S. Rosenberg,et al.  High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. , 1999, Journal of immunology.

[34]  J. Sprent,et al.  Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. , 1998, Immunity.

[35]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[36]  S. Snyder,et al.  RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Rolf M. Zinkernagel,et al.  Immunology Taught by Viruses , 1996, Science.

[38]  D. Snover,et al.  Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome. , 1993, Journal of immunology.

[39]  M. Bevan,et al.  Introduction of soluble protein into the class I pathway of antigen processing and presentation , 1988, Cell.